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Abstract
Background: The Fluorescence In Situ Hybridization (FISH) technique is a very useful tool for diagnostic and prognostic
purposes in molecular pathology. However, clinical testing on patient tissue is challenging due to variables of tissue
processing that can influence the quality of the results. This emphasizes the necessity of a standardized FISH protocol
with a high hybridization efficiency. We present a pretreatment protocol that is easy, reproducible, cost-effective, and
facilitates FISH on all types of patient material simultaneously with good quality results.
During validation, FISH analysis was performed simultaneously on formalin-fixed paraffin-embedded, fresh frozen and
cytological patient material in combination with commercial probes using our optimized one-fits-all pretreatment
protocol. An optimally processed sample is characterized by strong specific signals, intact nuclear membranes, non-
disturbing autofluorescence and a homogeneous DAPI staining.
Results: In our retrospective cohort of 3881 patient samples, overall 93% of the FISH samples displayed good quality
results leading to a patient diagnosis. All FISH were assessed on quality aspects such as adequacy and consistency of
signal strength (brightness), lack of background and / or cross-hybridization signals, and additionally the presence of
appropriate control signals were evaluated to assure probe accuracy. In our analysis 38 different FISH probes from 3
commercial manufacturers were used (Cytocell, Vysis and ZytoLight). The majority of the patients in this cohort
displayed good signal quality and barely non-specific background fluorescence on all tissue types independent of
which commercial probe was used.
Conclusion: The optimized one-fits-all FISH method is robust, reliable and reproducible to deliver an accurate result for
patient diagnostics in a lean workflow and cost-effective manner. This protocol can be used for widespread application
in cancer and non-cancer diagnostics and research.
Keywords: Fluorescence In Situ Hybridization, FISH, Pretreatment, Formalin-fixed paraffin-embedded, Fresh frozen,
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Background
Fluorescence In Situ Hybridization (FISH) is a widely used
approach to localize the presence or absence of a specific
genetic aberration that may potentially be associated with
tumor types or subtypes, cellular morphology, disease
prognosis, or response to targeted therapy [1]. FISH is a
molecular cytogenetic method that has advantages over
metaphase chromosome analysis by karyotyping because
it can be applied on both dividing (metaphase) and non-
dividing cells (interphase), the resolution is better whereby
detection of a small genetic aberration can be achieved
and it has a lower threshold for detecting small popula-
tions of abnormal cells (in low tumor percentage or low
mosaicism samples) [2]. By using fluorescent DNA probes
to hybridize entire chromosome regions or single unique
sequences, it serves as a powerful adjunct to classic mo-
lecular cytogenetics and pathology diagnostics [3]. FISH
involves the binding (or annealing) of fluorescence labeled,
target-specific nucleic acid probes to their complementary
DNA sequences and the subsequent visualization of these
probes within cells in the tissue of interest [4]. The detec-
tion of chromosomal rearrangements, amplifications and
deletions by FISH is well-accepted as a robust and reliable
technique [5]. The pretreatment procedure contains
essential steps to obtain an optimal fluorescent signal
which makes it crucial when conducting FISH analysis.
The technical challenge of applying FISH lies within the
pretreatment protocol. An efficient pretreatment protocol
should expose the target genes and allow the penetration
of the probes without significantly altering the integrity
and morphology of the tissue [6]. In the current study we
have developed a general pretreatment method in order to
standardize our FISH procedure for many tissue types and
probes produced by different manufacturers (Fig. 1). The
aim of this methods paper is to describe and introduce
our robust, in-house developed and cost-effective general
pretreatment FISH procedure that is validated according
to the diagnostics quality criteria within the molecular
pathology diagnostics and research.
Results
Sample characteristics
Of all 3881 patient samples included 3376 samples (87%)
were formalin-fixed paraffin-embedded (FFPE) material,
466 samples (12%) were cytological specimen and 39 sam-
ples (1%) were fresh frozen (FF).
FISH analyses results
Of the full cohort, 87% of the samples were tested with
Cytocell probes, 10% with ZytoLight probes and 1% with
Vysis probes (Table 1).
During the verification phase, all new probes were initially
assessed on 10 normal healthy tissue samples to determine
the adequacy and consistency of signal strength (brightness),
lack of background and / or cross-hybridization signals,
presence of appropriate control signals, sensitivity, specifi-
city, reproducibility and stability between runs from which it
was observed that < 10% (range 1–7%) of normal healthy tis-
sue cells displayed an aberrant signal pattern (break apart,
deletion, fusion, or amplification), due to biological hetero-
geneity or technical artefacts. However the threshold of 10%
aberration in normal tissue was never exceeded. Only those
probes with interpretable results in ≥95% of the cases were
implemented in the routine diagnostics. In addition the
probes were also tested on tumor tissue with a known or
suspected for the genetic aberrations to assess the accuracy
of diagnosis.
Image robustness for diagnostic analysis
Overall in our diagnostic cohort, 3609 slides (93%) of the
tested patient samples displayed good quality results lead-
ing to a patient diagnosis, whereas 272 slides (7%) displayed
uninterpretable results (Table 1). All diagnostic FISH re-
quests were assessed on quality aspects such as adequacy
and consistency of signal strength (brightness), lack of
background and / or cross-hybridization signals, and
additionally the presence of appropriate control signals to
assure probe accuracy. Patients with interpretable results
are considered for further treatment or diagnosis whereas
uninterpretable results are not. Uninterpretable results are
characterized by a poor cellular morphology, loss of /or low
fluorescent signal quality, and /or high background fluores-
cence signals. In the case of uninterpretable results alterna-
tive diagnostic experiments are conducted.
In order to determine the robustness of our optimized
pretreatment method on different tissue types with differ-
ent commercial probes, the FISH analysis was conducted
on FFPE, FF and agar embedded Cytological samples sim-
ultaneously for one gene. The FFPE, FF and cytological
tissue were all healthy specimens. The FFPE and FF sam-
ples were tested on tonsil tissue and the cytological sam-
ples were tested on agar embedded cells after a lymph
node puncture biopsy. As an example for protocol robust-
ness, our new diagnostic protocol was performed with the
Cyclin D1 (CCND1) FISH probe from Cytocell, Vysis, and
ZytoLight (Fig. 1). The Cytocell and ZytoLight CCND1
probes were break apart probes and the Vysis CCND1
probe was a fusion probe. As expected for healthy tissue,
all cases were negative for a gene rearrangement. Our
image results show good signal quality with low non-
specific background on all tissue types and with Cytocell,
Vysis and ZytoLight commercial probes (Fig. 2).
Protocol evaluation by external quality assessment schemes
Our optimized method achieved 100% concordance for
the HER2 FISH NordiQC - Quality Control 2015 evalu-
ation, 100% concordance for genotyping and clerical ac-
curacy for the sarcoma panel containing CHOP (DDIT3),
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FUS, EWSR1 and MDM2 in the UK NEQAS International
Quality Expertise 2016 evaluation. In addition 100% con-
cordance was achieved overall for the sarcoma panel con-
taining SYT (SS18), EWSR1 and FOXO1 in the UK
NEQAS International Quality Expertise 2017 evaluation.
And lastly 100% concordance was also achieved for the
cMYC (MYC) Dutch Foundation for Quality Assessment
in Medical Laboratories (SKML) 2017 evaluation.
Discussion
In this study we present a lean and cost-effective stan-
dardized FISH protocol applicable for all probes and
Fig. 1 A comparison of the FISH diagnostic workflows. The old diagnostic workflow comprised of various commercial methods from different
manufacturers that would be used simultaneously depending on the patient requests. The new diagnostic workflow uses one in-house
developed protocol for all patient samples. Additionally all reagents excluding probes are prepared in-house, making it very cost effective
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tissue types with a high hybridization efficiency. In our
cohort of 3881 patient samples, overall 93% of the tested
patients samples displayed good quality FISH results
leading to a patient diagnosis.
In pathology, the FISH technique is a very useful tool for
diagnostic and prognostic purposes [1]. However, clinical
testing on patient tissue is challenging due to various vari-
ables of tissue processing that may influence the quality of
the results. The effectiveness of the FISH technique can be
influenced by different factors such as, specimen age, initial
tissue handling, specimen fixation, paraffin-embedding and
fresh frozen artefacts [10]. The optimization of digestion
and post hybridization washing procedures are important
for achieving optimal hybridization conditions.
The pretreatment protocol we developed is easy,
reproducible, and facilitates FISH on formalin-fixed
paraffin-embedded, fresh frozen and cytological
patient material with the potential for widespread
application in cancer and non-cancer diagnostics and
research. In our experience the introduction of an add-
itional formalin fixation step for cytological and fresh
frozen samples has significantly increased signal
strength and reduced background and therefore the
interpretability of these cases.
Previous studies on FISH pretreatment methods de-
scribed the commonly used pretreatment agent sodium
thiocyanate as too harsh when applied to tissue, because
tissue sections were found to detach from the slides and
were susceptible to mechanical disaggregation [11, 12]. In
addition some studies suggested that the optimal concen-
tration, incubation time, and incubation temperatures, of
these pretreatment agents must be titrated for the differ-
ent tissue sections and tissue types [6, 13]. This would
suggest the use of multiple protocols for FISH in one
laboratory. Our old diagnostic workflow was comprised of
various commercial methods from different manufac-
turers that would be used simultaneously depending on
the patient requests. The new diagnostic workflow is lean
and uses one in-house developed protocol for all patient
samples. Additionally all reagents excluding probes are
prepared in-house, making it very cost effective. Leers et
al. and Tojo et al. suggested that the heating of cells in an
acidic environment with the pretreatment agent, citric
acid buffer followed by a proteolytic step improved the
fluorescent signals in FFPE tissue significantly [6, 13].
The presented method in this manuscript in combin-
ation with the use of citric acid buffer and proteinase K
digestion has shown to inflict minimal tissue damage,
Fig. 2 Representative FISH images of FFPE, FF and agar embedded cytological samples with Cytocell, Vysis, and ZytoLight CCND1 FISH probes
that were simultaneously processed using the developed standardized procedure. a FISH image of FFPE tissue labeled with Cytocell CCND1
Breakapart probe. b FISH image of FFPE tissue labeled with ZytoLight SPEC CCND1 Dual Color Break Apart Probe. c FISH image of FFPE tissue
labeled with CCND1 Vysis LSI Cyclin D1 (11q13) Spectrum Orange/ Vysis CEP 11 Spectrum Green fusion probe. d FISH image of FF tissue labeled
with Cytocell CCND1 Breakapart probe. e FISH image of FF tissue labeled with ZytoLight SPEC CCND1 Dual Color Break Apart Probe. f FISH image
of FF tissue labeled with CCND1 Vysis LSI Cyclin D1 (11q13) Spectrum Orange/ Vysis CEP 11 Spectrum Green fusion probe. g FISH image of
cytological agar embedded cells labeled with Cytocell CCND1 Breakapart probe. h FISH image of cytological agar embedded cells labeled with
ZytoLight SPEC CCND1 Dual Color Break Apart Probe. i FISH image of cytological agar embedded cells labeled with CCND1 Vysis LSI Cyclin D1
(11q13) Spectrum Orange/ Vysis CEP 11 Spectrum Green fusion probe
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and to preserve tissue morphology for a correct inter-
pretation of genetic aberrations within the sample. An
optimally processed sample is characterized by intact
nuclear membranes, non-disturbing autofluorescence
and a homogeneous DAPI staining. The majority of the
patients in this cohort displayed good signal quality with
low non-specific background on all tissue types with dif-
ferent commercial probes. Cases that were classified as
uninterpretable were mainly due to increased non-
specific background signals, primarily in cases in which
additional single signals are of clinical relevance and also
generally due to a lack of signal within the nucleus.
Previous FISH methods within our laboratory consisted
of multiple kits from various manufacturers that were
ideally optimized for a distinct tissue type and probe
manufacturer, therefore significantly reducing the amount
of slides simultaneously processable per run. The major
benefit of our presented protocol is the assurance that all
tissue types and different probe manufacturers are pro-
cessable simultaneously with good quality results.
In terms of appropriate control signals and accuracy of
diagnosis, our FISH method has repeatedly confirmed its
reliability by means of External Quality Assessment
schemes on a national and international level. The opti-
mized pretreatment method has been used to test samples
for the NordiQC - Quality Control, UK NEQAS Inter-
national Quality Expertise and the Dutch Foundation for
Quality Assessment in Medical Laboratories (SKML)
interlaboratory comparisons studies to check the ability of
laboratories to deliver accurate testing results.
Although all variables are well defined in the opti-
mized pretreatment protocol the tissue type will always
remain a risk factor. Being a reference center experi-
enced with FISH, specimen are received from various
medical centers in the Netherlands and abroad, where
each center has their own methods of tissue processing.
Nevertheless, those patients included in this cohort per-
formed equally well as our in-house processed samples.
In conclusion the optimized one-fits-all FISH method
as presented in this paper is lean, robust, reliable and
reproducible for all probes and tissue types facilitating a
rapid turnover with a high hybridization efficiency and
detection to deliver an accurate diagnosis to patient
diagnostics in a cost-effective manner.
Materials and method
The optimized FISH protocol was used to facilitate rou-
tine FISH analysis in a molecular diagnostic setting. FISH
analysis was performed on 3881 patient samples included
from July 2016 until July 2018 in the University Medical
Center Utrecht (The Netherlands) according to the vali-
dated pretreatment FISH method for in vitro diagnostic
testing (laboratory accreditation ISO15189). Clinical test-
ing on patient material was conducted in compliance to
the General Data Protection Regulation (GDPR) as defined
by the European Union. Initially, the performance charac-
teristics of 38 commercial probes from Vysis (Abbott
Laboratories, Illinois, U.S.A.), Cytocell (Cytocell Ltd., Cam-
bridge, United Kingdom) and ZytoLight (ZytoVision
GmbH, Bremerhaven, Germany) were each assessed on 10
normal healthy tissue samples. After validation on healthy
tissue slides, probes were tested on diseased tissue material
where at least one sample was included that contained the
suspected genetic aberration. After validation of the probe,
the method is applied in the routine diagnostics setting of
the Molecular Pathology department. Tissue samples
included in this analysis were formalin-fixed paraffin-
embedded (FFPE), fresh frozen (FF), or from cytological
specimen.
Formalin-fixed paraffin-embedded material
FISH analysis was mainly performed on 4-μm FFPE tissue
sections mounted on charged slides (Surgipath X-tra Adhe-
sive precleaned Micro slides, Leica Microsystems,
Amsterdam, The Netherlands). The tissue slides were incu-
bated at 56 °C for 1–24 h and subsequently deparaffinized
in a xylene series and dehydrated in an alcohol series.
Formalin-fixed tissue is suitable for clinical diagnostics due
to the fact that induced protein-protein and protein-
nucleic acid cross-links preserves the tissue efficiently,
while retaining morphology relatively intact [12, 14]. How-
ever, the macromolecular network introduced by formalin,
significantly reduces the access of FISH probes to target
DNA [12]. The initial steps in the FISH pretreatment
protocol diminishes this formalin induced network.
Cytological and fresh frozen material
Cytological samples included cellient prepared cells, agar
embedded cells, blood smears and cytospin materials
[15]. In the case of fresh frozen, cellient and agar
blocked material, FISH analysis was performed on 4-μm
sections mounted on charged slides. The cellient and
agar blocked slides were incubated at 56 °C for 1–24 h
and subsequently deparaffinized in a xylene series and
dehydrated in an alcohol series. Prior testing has shown
an enhanced probe performance when cytological (celli-
ent prepared cells, agar embedded cells, blood smears
and cytospin materials) and fresh frozen samples slides
were incubated for 16–24 h in a 4% Formaldehyde
solution (10% formalin) (Propath bvba, Ronse, Belgium)
before proceeding to pretreatment.
Fluorescence In Situ Hybridization procedure;
pretreatment, probe hybridization, post hybridization
wash and DAPI counterstaining
The prepared slides were pretreated for 20 min with 0.2
N HCL at room temperature and incubated 20min at
100 °C in a 10mM citrate buffer solution pH 6.0. The
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pretreatment with hydrochloric acid (HCL) aids in solu-
bilizing basic nuclear proteins, improving the accessibil-
ity of the DNA. This method extracts the extracellular
matrix of proteins which potentially limit the accessibil-
ity of the probe to the cells, preventing tissue autofluo-
rescence [12]. Pretreated tissue was digested 10 min in
10mg/ml digestion buffer pH 7.0 (1M Tris-HCL, 0.5M
EDTA, 5M NaCl) and Proteinase K (Sigma- Aldrich,
Zwijndrecht, The Netherlands) at 37 °C. Proteinase K
digestion is the most crucial step in this protocol in
order to obtain technically optimal FISH results [12, 14].
The breaking of peptide bonds by protease digestion dir-
ectly affects signal quality, allowing access of the FISH
probes to the genomic target DNA and reduces autoflu-
orescence generated by intact proteins [12]. Proteinase K
digestion was stopped by dehydrating slides in an alco-
hol series and air-dried. Cytocell and ZytoLight probes
were ready to use, Vysis probes were diluted according
to manufacturer’s instructions. Throughout the pretreat-
ment validation multiple probe batches were evaluated
to determine the variability and reproducibility of the
FISH assay. Probes were applied to the tissue slide, cover
slipped and sealed with rubber cement. Denaturation was
conducted at 78 °C for 5min and hybridized 12–18 h at
37 °C in a humidified ThermoBrite system (Abbott Mo-
lecular, Des Plaines, Illinois, U.S.A.). Post hybridization
washing in 2XSSC/0,1% NP-40 pH 7.0 (Boom B.V., Mep-
pel, The Netherlands) to soak off coverslip and stringent
wash at preheated temperature of 74 °C in 0.4XSSC/
0.3%NP-40 pH 7.0 to remove undesired hybrids of low
homology. Subsequently, the slides were rinsed in 2XSSC
pH 7.0, then in Phosphate Buffered Saline (PBS) (Lonza,
Walkersville, Maryland, U.SA.) and lastly in Milli-Q. Slides
were dehydrated in an alcohol series. Air dried slides were
counterstained using Vectashield with DAPI hardset
mounting medium (Brunschwig Chemie, Amsterdam, The
Netherlands) and cover slipped. Slides were stored at −
20 °C if not analyzed immediately.
Slide imaging and analysis
Before capturing FISH images adjacent hematoxylin and
eosin (H&E) stained sections were analyzed for regions
containing tumor. These areas were circled using a dia-
mond tipped pen, and the same regions on the FISH
slide were examined for molecular DNA aberrations in
the nuclei. Following tissue matching, images were cap-
tured at 63x magnification with automatic Z-stack and
used for analysis on the Leica automatic DM6000 Scan-
ner (Leica Microsystems, Amsterdam, The Netherlands)
in combination with CytoVision software (Applied Im-
aging, Newcastle, United Kingdom). A sufficient number
of fields (> 6) per sample were captured and were visual-
ized containing minimally 100 interpretable nuclei. The
software analysis was divided into two parts; (1) segmen-
tation, and (2) classification. Segmentation is the identifi-
cation of nuclei (DAPI stained) by the software and
classification involves the identification of nuclear signal
patterns (green or red fluorescence probe signals) and
their classification in categories (e.g. as non-rearranged
or rearranged). Segmentation and classification are error
prone, due to the heterogeneity associated with imaging
of tissue sections, 3D characteristic of tissue slides in
pathology (whereby cells might overlap in images and
tissue sectioning artefacts), and Z-stack analysis [16].
The FISH images required manual editing before final
analysis, which involved correcting automated classifi-
cation errors due to inaccurate nuclear detection.
Nuclei without signal were manually excluded from the
analysis. The remaining nuclei were examined for signal
accuracy. Finally, additional nuclei were manually
added to the analysis if there were insufficient nuclei
identified by the analysis software. Additional nuclei
were chosen if the contour could be easily identified.
During FISH analysis cells were scored into categories
based on probe type (Table 2). The criteria after which
a case can then be considered aberrant or not aberrant
varies per probe.
Table 2 Categories for digital FISH image analysis per probe type
Breakapart probe Fusion probe Amplification probe
Normal (2F) Normal (2R, 2G) Normal (2R, 2G)
One pair (1F) One pair (1R, 1G) Ratio - Not amplified (ratio 1, ≥3R, ≥3G)
Breakapart (1F, 1R, 1G) Fusion (1(− 2)F) Ratio - Gaina
Single red (1F, 1R) Single red (2G, 1R) Ratio - Amplifieda
Single green (1F, 1G) Single green (2R, 1G) Copy number - Not amplifieda
Extra red (2F, ≥1R) Extra red (2G, ≥3R) Copy number - Gaina
Extra green (2F, ≥1G) Extra green (2R, ≥3G) Copy number - Amplifieda
Gain (3 - 8F) Gain (3 – 8R, 3 – 8G)
Amplification (≥8F) Amplification (≥8R, ≥8G)
F Fusion signal, R Red/Orange signal, G Green signal
aCriteria varies per probe as described in the legends of Table 1
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Quality of FISH results
During the verification phase of new probes quality
requirements were assessed on 10 normal healthy tissue
samples prior to implementation. It is required that the
adequacy and consistency of signal strength (brightness),
lack of background and / or cross-hybridization signals,
presence of appropriate control signals, sensitivity, speci-
ficity, reproducibility and stability between runs be
determined. For a probe to be considered reliable for
implementation within the routine diagnostics ≥95% of
cases evaluated need to be considered interpretable
(acceptable). If this is not achieved the probe was
considered unreliable for diagnostic application.
Considering our FISH application within a routine diag-
nostic laboratory, quality guidelines are established to
assure reliable patient results are reported. All diagnostic
patients in this cohort were random. Patients samples were
not grouped into different quality groups but were consid-
ered of sufficient quality or not to allow a reliable patient
result to be given. Therefore the required quality aspects
(adequacy and consistency of signal strength (brightness),
lack of background and / or cross hybridization signals,
and additionally the presence of appropriate control sig-
nals) were evaluated for each patient after which the results
obtained from each diagnostic patient is considered inter-
pretable or uninterpretable. Patient samples with interpret-
able results were considered for further treatment or
diagnosis whereas uninterpretable (unacceptable) results
were not. These uninterpretable FISH results were charac-
terized by a poor cellular morphology, loss of /or low
fluorescent signal quality, and /or high background fluores-
cence signals from which no reliable patient diagnosis can
be given. In the case of uninterpretable results alternative
diagnostic experiments are conducted.
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